Eculizumab in secondary atypical haemolytic uraemic syndrome

Teresa Cavero; Cristina Rabasco; Antía López; Elena Román; Ana Ávila; Ángel Sevillano; Ana Huerta; Jorge Rojas-Rivera; Carolina Fuentes; Miquel Blasco; Ana Jarque; Alba Pena García; Santiago Mendizábal; Eva Gavela; Manuel Macı́a; Luís F. Quintana; Ana Romera; J Borrego; Emilia Arjona; Mario Espinosa; José Pórtoles; Carolina Gracia-Iguacel; Emilio González‐Parra; Pedro Aljama; Enrique Morales; Mercedes Cao; Santiago Rodrı́guez de Córdoba; Manuel Praga

doi:10.1093/ndt/gfw453

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Short treatment with eculizumab can result in a rapid improvement of patients with secondary aHUS in whom TMA has persisted and renal function worsened despite treatment of the TMA-inducing condition.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cavero et al. (2016) studied this question.

synapsesocial.com/papers/69d778caf44a16d01ef314a2 https://doi.org/10.1093/ndt/gfw453

View Full Paper

Ask AI

Bookmark

Share

Eculizumab in secondary atypical haemolytic uraemic syndrome

Ask about this paper

Abstract

Discussion

Cite This Study

Eculizumab in secondary atypical haemolytic uraemic syndrome

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading